IBPS Biosimilar Development Update
IBPS Covid-19 CT Update V
Our first white paper, Biosimilars Come of Age, highlighted growth in Biosimilars from 2015 to 2020.
Based on FDA guidance on GMP considerations for Responding to COVID-19 infection in employees in Drug and Biological Products Manufacturing
IBPS Covid-19 CT Update IV
In the 1990s, it was “generic biologics”. In the early 2000s, “follow-on biologics”. Starting in 2006 regulators settled on the word “biosimilars.” The goal was always the same..
IBPS and SBLehrer LLC are releasing the next update of clinical efforts for treatments and vaccines for Covid19
IBPS and SBLehrer LLC are releasing the next update of clinical efforts for treatments and vaccines for Covid19.
COVID-19 has many names; Coronavirus, Covid-19 or SARS-CoV-2. Worldwide pandemic triggered by this virus has prompted an unprecedented amount..
Global biosimilar market is currently driven by presence of a large geriatric population and increase in the prevalence..
An Indian generic pharmaceutical giant was keen on developing in-house biosimilars to expand its portfolio in the domestic as well as global markets.
how technical writing opportunities have proliferated in the drug development market in India..
As the regulatory landscape is evolving for biosimilars, the intriguing challenges for the biosimilar development companies and manufacturers..
October being the Breast Cancer awareness month, we thought that a discussion on breast cancer in India would be most appropriate to start the IBPS blog
© IBPS consulting 2018